A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials by Selker, H. P. et al.
nature publishing group state          art
see COMMENTARY page 131
This article proposes an “efficacy-to-effectiveness” (E2E) 
approach to clinical trials that includes a seamless transition 
from efficacy to effectiveness trials. Our proposal is structured 
to capture the benefits of an integrated E2E approach without 
delaying regulatory review and approval. This approach offers 
logistical advantages by minimizing start-up costs by using the 
existing efficacy trial infrastructure. More important, it offers 
the opportunity for improved understanding of how a treat-
ment will work in practice in patients with a typical range of 
characteristics, comorbidities, and treatment adherence, such 
as those seen in more usual clinical settings.
In addition to these medical benefits, facilitation of early 
effectiveness results could have a role in the availability and 
use of treatments. Payers point out that efficacy trials are nec-
essary but not sufficient to inform decisions about payment 
coverage and reimbursement. Lack of clear demonstration of 
comparative clinical and economic value in usual care settings 
has increasingly resulted in outright denial of coverage, cost 
pass-through to patients through copayments (in the United 
States), and formulary restrictions of use. These conditions 
provide strong incentives for pharmaceutical companies 
with novel and effective treatments to provide comparative 
effectiveness data as close in time as possible to marketing 
approval.
An E2E approach does face hurdles. In generating data, the 
potential benefits to all stakeholders will have to be balanced 
along with the incremental cost of such a design and the poten-
tial perceived dilution of treatment effect due to use in a more 
heterogeneous population. Acceptance by sponsors will require 
addressing the technical challenge of broadening inclusion cri-
teria to increase heterogeneity while retaining sufficient statis-
tical power in the face of greater variability. Acceptance also 
will require demonstrating the net benefits of the E2E effec-
tiveness components to sponsors, regulators, payers, patients, 
and providers. Indeed, we believe that the benefits of an E2E 
approach will in many instances outweigh the risks and value 
for all stakeholders.
CURRENT TRIALS SEPARATE EFFICACY AND EFFECTIVENESS
Both efficacy and effectiveness trials provide useful informa-
tion for health-care decision makers, patients, clinicians, health 
plans, other payers, and regulators.
We propose an “efficacy-to-effectiveness” (E2E) clinical trial design, in which an effectiveness trial would commence 
seamlessly upon completion of the efficacy trial. Efficacy trials use inclusion/exclusion criteria to produce relatively 
homogeneous samples of participants with the target condition, conducted in settings that foster adherence to rigorous 
clinical protocols. Effectiveness trials use inclusion/exclusion criteria that generate heterogeneous samples that are 
more similar to the general patient spectrum, conducted in more varied settings, with protocols that approximate 
typical clinical care. In E2E trials, results from the efficacy trial component would be used to design the effectiveness trial 
component, to confirm and/or discern associations between clinical characteristics and treatment effects in typical care, 
and potentially to test new hypotheses. An E2E approach may improve the evidentiary basis for selecting treatments, 
expand understanding of the effectiveness of treatments in subgroups with particular clinical features, and foster 
incorporation of effectiveness information into regulatory processes.
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•	 Efficacy trials are designed to establish the existence of a 
treatment effect under optimal conditions. To this end, effi-
cacy trials use exclusion criteria that yield relatively homo-
geneous samples of participants, and are conducted in 
settings that foster adherence to carefully specified clinical 
protocols, often for shorter periods than those ultimately  
used in general patient care. Efficacy trials are used to 
secure regulatory approval with labeling of appropriate 
conditions of use.
•	 Effectiveness trials are designed to establish whether treat-
ment effects identified in efficacy trials carry over to more 
typical use of drugs in practice. To this end, effectiveness 
trials use broader inclusion and narrower exclusion crite-
ria, which produces heterogeneous samples that represent 
a usual patient spectrum; they are conducted in more 
varied clinical settings that approximate usual practice 
conditions, and they use treatment protocols that approxi-
mate typical clinical standards of care and durations of 
treatment.
In current practice, efficacy and effectiveness trials are con-
ducted separately, with effectiveness trials typically done years 
later, if at all.1–4 Therefore, approval and introduction of new 
drugs are currently based on results from optimized patient 
samples and ideal conditions, without data on effectiveness in 
usual clinical care that could be generalizable to the broader 
population and conditions in which the new medication ulti-
mately will be used.
The path to postapproval effectiveness trials is a road not often 
taken. In a typical drug development program, a promising drug 
candidate is identified, early-phase safety and dosing studies are 
conducted, and targeted efficacy trials are done. If these succeed, 
marketing approval and publication may follow. Once a drug is 
approved, developers are unlikely to support an effectiveness 
trial. The reasons for this may be that with more heterogene-
ous populations and poorer signal-to-noise ratios, effectiveness 
trials often show lesser effects than the efficacy trials on which 
licensing decisions were based. Furthermore, more toxicity may 
be found when used with more typical regimens and in general 
populations.5 If independent funding is found for a postapproval 
effectiveness trial, those conducting it may or may not have the 
involvement of the original investigators, may not have access 
to information that would inform understanding of the hetero-
geneity of effects in various subgroups, and may not have access 
to efficacy trial data that could generate predictive models to 
facilitate translation into widespread use. As an alternative to 
this uncertain and disjointed process, we suggest the integrated 
continuous translational research process described below.
PROPOSED APPROACH
Elements of integrated E2E trials
With the E2E approach, as planned from the outset, potentially 
including patients and other stakeholders, an effectiveness trial 
starts immediately after the efficacy trial component is com-
pleted. (Here, we use as context trials in which the comparator 
is a placebo rather than an alternative active agent, as is usually 
the case in efficacy trials, but the E2E method also should be 
applicable to comparative efficacy and effectiveness.) The transi-
tion could be handled in a variety of ways; one could be that an 
external data safety monitoring board (DSMB) would review the 
data and analytic methods of the efficacy trial and then ratify the 
results, using go/no-go criteria prespecified by investigators, the 
sponsor, and the responsible regulatory agency. Approval by the 
DSMB would trigger the start of the regulatory approval process 
and the transition from the efficacy trial to an effectiveness trial. 
At this point, the composition of the DSMB for the effectiveness 
component would be determined, potentially retaining some 
members and adding others. Although a pause between the effi-
cacy and effectiveness components might occur as sites are added 
and entry criteria and data collection are adjusted, because this 
transition was planned with criteria prespecified from the outset, 
it should be short and efficient. Then, as screening of popula-
tions for the effectiveness trial with less restrictive criteria ensues, 
some patients who would have been “screen failures” for the effi-
cacy trial component might become appropriate subjects for the 
effectiveness trial component. Thereby, these results will be more 
applicable to a general population than the results of the efficacy 
trial component (Supplementary Appendix online).
The use of protocols more typical of usual care, with more 
diverse participants, and in a wider range of clinical settings 
may be expected to alter, perhaps more often diminish, the 
net (average) treatment effect. Heterogeneity of the treatment 
effect across the study sample may mute average effective-
ness. However, this heterogeneity will also offer opportunities 
to detect how patient characteristics affect treatment effects. 
Divergence of individual and subgroup treatment effects from 
the overall average result will occur in both directions. In an 
overall negative trial, individuals or groups may be detected 
who benefited from treatment, whereas in an overall positive 
trial, individuals or groups may be detected for whom benefits 
did not outweigh risks.6,7 These differences also could signifi-
cantly change the cost–benefit analysis for use of a treatment.8 
It would not be warranted to use such results to alter regulatory 
approval that was based on efficacy data, but such insights from 
the effectiveness component could inform care and reimburse-
ment decisions. Such information about the heterogeneity of 
treatment effects from the effectiveness trial component could 
be represented in multivariable predictive models, described 
further below, to aid treatment decisions in the care of individu-
als. In addition to these dimensions, in some cases, hypotheses 
generated by findings in the efficacy trial component about rela-
tionships between clinical characteristics and treatment effects 
could be prespecified and formally tested in the effectiveness 
portion. In such cases, the effectiveness component would 
include targeted data collection to test such hypotheses.
The effectiveness portion will differ from the efficacy por-
tion in its specification of participants, treatment settings, and 
the protocol, but such differences will need to be compatible 
with the request for approval by the licensing authority on 
the basis of the efficacy trial component. Enrollment may be 
by primary-care physicians or community-based specialists 
rather than by special study sites, care will be more typical of 
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community settings, and protocol adjustments may include 
reductions in detailed data collection (and possibly the addi-
tion of assessments to test new hypotheses and heterogene-
ity of treatment effects), but the use of the drug would not 
be beyond the label indications being sought. Before initia-
tion of effectiveness trials, regulatory agencies and the DSMB 
review the prespecified transition and the differences between 
effectiveness and efficacy trials, including relaxed entry cri-
teria and longer duration, to confirm that the plan is still 
appropriate.
Statistical framework
Both efficacy and effectiveness components of E2E studies will 
be randomized controlled clinical trials, with sample size based 
on prespecified α and statistical power. Changes, including new 
hypotheses, could be incorporated into the effectiveness portion 
before its start, in a manner consistent with the adaptive clinical 
trial criteria of the US Food and Drug Administration. Although 
the E2E transition is not framed as an adaptive sequence, there 
may be circumstances in which adaptive and other features 
might be incorporated into the efficacy and/or effectiveness 
portions. Although the data from the efficacy portion might 
be used to formulate appropriate hypotheses for testing in the 
effectiveness portion, in the analysis of trial results, data from 
the two stages will not be combined. This facilitates interpret-
ability of the inference and ensures control of type 1 error for 
each stage separately.
When data from the efficacy trial are used to formulate ques-
tions to investigate in the effectiveness portion, the hypotheses 
will fall into two categories. The first consists of a small number 
of primary or coprimary hypotheses intended for formal test-
ing, controlling for type 1 error with appropriate adaptive or 
multiplicity adjustments. The second includes a larger number 
of secondary hypotheses, intended for exploratory investigation 
only, without control of type 1 error. Many hypotheses will test 
for interactions between treatments and preselected subgroups. 
To test these hypotheses, participant characteristics in the effec-
tiveness portion must include subject attributes with which 
treatment effects may interact. In some settings, the efficiency 
of effectiveness trials could be improved by introducing adap-
tive interim analyses with decision rules for dropping subgroups 
that do not appear to benefit from the new treatment.9,10 For 
primary hypotheses, subgroups, decision rules, and statistical 
methods for hypothesis testing would have to be prespecified to 
maintain the validity of conclusions. For secondary hypotheses, 
the objective would be to identify potential treatment-modifying 
influences to inform future hypothesis testing.
For primary hypotheses, because the effectiveness portion 
will have more diversity in participants and settings, standard 
deviations will generally be larger and overall differences smaller 
than in the efficacy portion. Thus, to detect a given effect, larger 
sample sizes will be needed. In cases in which the confirmation 
of effects seen in the efficacy trial is the primary objective, a 
larger sample size will be warranted. In other cases in which the 
objective is hypothesis generation or the development of predic-
tive models, larger sample sizes may not be needed.
E2E-derived clinical predictive instruments as decision aids
Separate from these analyses of E2E trial results, but still repre-
senting treatment effects, data from both trial components could 
be used in multivariable patient-specific predictive models of 
treatment benefits. Examples include “clinical predictive instru-
ments,” logistic regressions that generate 0–100% predictions 
of diagnoses and/or outcomes as decision support in real-time 
care. The independent variables in these models include clinical 
and biological features and how patient characteristics and treat-
ments interact, with the dependent variables being the clinical 
outcomes of interest, and the ultimate goal being the improve-
ment of patient-specific treatment decisions.
An example of this approach is the thrombolytic predictive 
instrument (TPI), used for assessing patient-specific benefit 
of coronary reperfusion therapy for ST elevation myocardial 
infarction.11 Created using data from multiple trials and reg-
istries of patients with ST elevation myocardial infarction, the 
TPI’s multivariable logistic regression models include key patient 
characteristics predictive of key clinical outcomes, and interac-
tion variables to capture treatment effects and predict 30-day 
mortality, 1-year mortality, cardiac arrest, major bleeding, and 
stroke. When the patient’s individualized predictions of treat-
ment benefits are printed on text headers of electrocardiograms, 
clinician use of reperfusion is improved for patients with less 
obvious ST elevation myocardial infarctions, for women with 
ST elevation myocardial infarction, for patients in whom rep-
erfusion typically is underused, and for patients seen in settings 
with limited on-site relevant expertise.12 Thereby, clinical trial 
data based on heterogeneous samples can be used to support 
patient-personalized treatment by representing the heterogene-
ity of treatment effect among diverse patients. Another example 
of a predictive model based on trial data from heterogeneous 
populations is the Stroke-TPI, which identifies patients who 
may benefit from thrombolytic therapy for stroke.13 Another 
example predicts the probability that a patient receiving breast 
cancer chemotherapy will benefit from bone marrow growth 
factor treatment to counter suppression of white blood cells by 
chemotherapy.14 These examples show how clinical trial data, 
especially with the heterogeneity of effectiveness trials, can be 
used to support individualized treatment.
As electronic health records become more ubiquitous, such 
predictive models based on E2E trial data could become elec-
tronic health record–based clinical decision support.15 Thereby, 
individual treatment decisions could inform clinicians and 
patients about likely treatment outcomes on the basis of char-
acteristics acquired from the electronic health record. In addi-
tion to indicating when one treatment option is more likely to 
benefit the patient than another, it also could help identify situ-
ations in which there is strong uncertainty regarding the best 
treatment for a patient. This is analogous to the justification 
for conducting a randomized clinical trial when there is “clini-
cal equipoise” between treatment options. When equipoise is 
based on predictions of model-based predictive instruments, 
this has been termed “mathematical equipoise.”15 (e.g., the TPI 
has been modified to predict a patient’s risk for 30-day mortality 
if treated and if not treated (i) with thrombolytic therapy and 
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(ii) by an alternative type of reperfusion, namely, percutaneous 
coronary intervention). By its simultaneous predictions of both 
treatments’ outcomes (in addition to that from no treatment), 
this “percutaneous coronary intervention–TPI” indicates when 
one form of reperfusion has a better predicted outcome than 
the other, so it can immediately be offered to the patient.15,16 It 
also can indicate when there is essentially equivalence—equi-
poise—between the two forms of reperfusion. From a research 
perspective, where such equivalence exists, randomization into 
treatment groups may be justified; from a clinical perspective, 
this could foster informed conversations between clinicians and 
patients on factors such as risk, uncertainty, preferences, and 
choices.
DISCUSSION
We propose an integrated E2E trial approach with the following 
features:
•	 The first portion will be a standard randomized controlled 
efficacy trial, conducted with relatively homogeneous 
populations, powered to detect evidence of superiority 
over placebo or active control.
•	 The second portion will be an effectiveness trial, con-
ducted in usual care settings using a more heterogene-
ous sample that is representative of the expected patient 
spectrum.
•	 If it is intended that a primary effect seen in the efficacy 
portion is to be confirmed in the effectiveness portion, the 
sample size of the effectiveness component will need to be 
increased because net average differences between treated 
and untreated subjects will probably be smaller and vari-
ability will probably be larger.
•	 For the intent of generating hypotheses on possible specific 
effects based on subpopulations or circumstances, samples 
will need to include sufficient numbers of subjects with 
those characteristics that may be associated with treatment 
effects, to permit detection of interaction effects.
•	 To enable development of predictive models for use in 
clinical settings, effectiveness trials should include hetero-
geneous populations and analytic approaches that allow 
detection of interactions between patient characteristics 
and treatment effects.
•	 To improve the E2E approach to trials, adaptive designs 
could be used within both the efficacy and effectiveness 
portions for interim assessments and modifications.
Although the E2E concept is simple, some practical barriers to 
implementation require consideration, including the following 
questions, which are addressed in the next section:
•	 Why would a company that has obtained, or anticipates 
obtaining, a positive result from an efficacy trial support 
an E2E effectiveness trial with the attendant possibility of a 
null result?
•	 What benefits would the E2E sequence provide for the 
public, for regulators, and for payers?
•	 What process issues need to be addressed in the imple-
mentation of E2E trials?
•	 What drugs and/or indications would be suitable for first 
applications of E2E?
Why would a drug manufacturer support an E2E trial?
After an efficacy trial has shown significant treatment effects and 
licensing has been granted, manufacturers are reluctant to sup-
port follow-up effectiveness trials. If an effectiveness trial were 
to reveal reductions in average effects or in specific subgroups, 
a manufacturer might face reductions in use, limits on the scope 
of reimbursements, or even a reversal of regulatory approval. To 
create incentives for manufacturers to participate in E2E trials, 
a balanced solution that provides benefits to manufacturers as 
well as patients, payers, and providers is needed. Various aspects 
of this problem deserve attention:
1.	 Effectiveness trials conducted in usual care settings with 
heterogeneous populations will typically show less thera-
peutic effect and more adverse effects than efficacy trials. 
To the extent appropriate, established drug approvals 
based on efficacy results should not be at risk for reversal if 
average effects decline in effectiveness trials.
2.	 The exploration of heterogeneity of treatment effects may 
identify special benefits and/or support development of 
predictive instruments that facilitate optimal use. A formal 
avenue for incorporating such insights into marketing 
could improve use of treatments while creating incentives 
for manufacturers. Moreover, as market forces in medi-
cal care turn from fee-for-service/product to payment for 
measured outcomes, along with other entities, manufac-
turers will become increasingly responsible for ultimate 
outcomes. In this context, the ability to identify potentially 
good vs. poor responders will be important.
3.	 Effectiveness studies based on more heterogeneous popu-
lations may provide justification for expansion of original 
eligibility criteria. If an efficacy trial is based on a narrow 
population that excludes potential beneficiaries, conduct-
ing a broader effectiveness trial may offer a potential 
justification for expansion of use without risking market 
approval.
4.	 Data on subgroup-specific benefits in heterogeneous 
populations in effectiveness trials may provide a basis for 
reexamining initial negative findings on promising drugs 
for which expected general effects did not materialize. 
In an environment that increasingly focuses on patient-
optimized treatments and cost-effectiveness, this approach 
may become a helpful part of introducing and sustaining 
new treatments.
One proposal that could be attractive to manufacturers could 
be the combination of the E2E effectiveness trial component 
with the initial authorization stage of recent proposals for adap-
tive licensing;17 this could be well suited to the development 
and assessment of drugs with heterogeneous effects. If an E2E 
approach were to be embedded in proposed adaptive approaches 
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to drug licensing, sponsors may be able to secure market access 
for drugs, potentially reinforced by payers, that provide benefits 
for specific subgroups but do not now pass the usual thresh-
olds for approval. From the perspective of manufacturers, this 
creates an opportunity to salvage drugs that would be killed in 
the late stages of development under the current development 
paradigm.
Disincentives to manufacturers could be reduced in a number 
of ways. If there are few agents in the marketplace, and especially 
if understanding heterogeneity of treatment effects might be 
critical to the use and marketing of a drug, the E2E effectiveness 
trial portion might well be attractive. For example, in Alzheimer’s 
disease and traumatic brain injury, there are no highly successful 
agents today. A broad effectiveness trial that collected indicators 
of heterogeneity that could be used for subsequent identifica-
tion of therapeutic responders, (such as specific types of illnesses, 
comorbidities, biomarkers, and/or genetic information) could 
support access to effective treatment for targeted patient groups. 
This also would be the case in areas in which there are some less 
than fully satisfactory agents, such as in Parkinson’s disease or 
metastatic cancer. Furthermore, explanatory factors for hetero-
geneity of effects, identifiable by biomarkers, genetics, or other 
characteristics, might be attractive to all involved.
How would patients, providers, payers, and regulators benefit 
from E2E trials?
Information on the optimal use of treatments is a public good, 
with significant value to patients, providers, payers, and regu-
lators. As with many public goods, there is underprovision of 
information on the effects of treatments in actual use, particu-
larly with respect to understanding of rare adverse events and 
the benefits and risks for large but vulnerable subgroups.
The use of larger and more varied samples in the E2E effective-
ness portion may facilitate the detection of uncommon adverse 
effects. The larger numbers will help uncover rare events, and 
inclusion of a wider range of individuals, ages, and comorbidi-
ties may expose propensities for adverse effects. Conducting 
the effectiveness phase of the E2E trial as soon as feasible will 
increase the likelihood of early detection of rare adverse effects, 
to the benefit of the public and all other stakeholders. This could 
be a useful adjunct to the use of registries and monitoring net-
works that seek to detect such effects in general use.
Prelicensing efficacy trials often fail to provide useful informa-
tion on the benefits and risks of treatment to the most vulner-
able subgroups. The elderly, the frail, and those with multiple 
comorbidities are an increasing segment of target populations 
in actual care, but these groups are often excluded from popula-
tions in efficacy trials. Together with providers and regulators, 
both private and public payers have expressed an interest in 
extending the evidence base in trials to include such under-
represented groups to improve assessments of efficacy, safety, 
and effectiveness.
For examples of how E2E may enable better identification 
of a responder population, consider the use of estrogen recep-
tor testing to direct hormone-based treatments and the use of 
immunocytochemistry and gene amplification studies to define 
the worth of trastuzumab (Herceptin) to treat breast cancer. The 
use of a companion diagnostic test for either estrogen receptor 
or human epidermal growth factor receptor-2 (HER2) may help 
identify susceptible tumors. Trastuzumab was developed with a 
development plan to screen-in potential responders and screen-
out expected nonresponders. Yet correlating estrogen receptor 
or HER2 positivity and hormone or trastuzumab responsiveness 
remains a complex process, reflecting variability in the testing 
process and other factors in the population that may influence 
outcomes.18–21 The effectiveness portion of an E2E trial might 
provide an opportunity to better identify a responder popula-
tion in this case.
Finally, there may be benefits to patients, providers, pay-
ers, and regulators—and to manufacturers—in aligning E2E 
with proposed adaptive approaches to drug licensing. The 
E2E approach is premised on gathering information on wider 
effectiveness as early as possible, before full licensing, but with-
out delaying market authorization. Under current licensing 
pathways, binary approval or disapproval decisions are based 
largely on randomized efficacy trials with confounder-cleansed 
populations. Adaptive approaches to licensing are intended to 
create a more flexible option between approval and rejection 
of drugs. Eichler et al. have assessed the benefits of adaptive 
approaches to licensing with iterative phases of evidence gath-
ering and reassessment over the life cycle of drugs.17 During 
the initial authorization phase, patient access to drugs would 
be managed to limit exposure to risks while information on the 
efficacy and safety of drugs in use is accumulated. Regulators 
in Europe, Singapore, Canada, and elsewhere are now actively 
considering initiation of pilot adaptive licensing projects with 
initial authorization phases. If pilots are initiated, then initial 
authorization periods could potentially be structured to provide 
information on effectiveness along with efficacy and safety. This 
will require consideration of the extent to which E2E would 
provide data needed for licensing.
What design issues must be addressed to implement E2E 
 trials?
Although there are many nuances, the key issues for efficacy trial 
design are generally well understood. By contrast, the more vari-
able design and implementation aspects of effectiveness trials are 
less well understood and, in the context of the E2E approach, 
will require further research.
First, there is no agreement on how to secure generalizable 
results through wider inclusion  and/or on basing study samples 
on standards of usual care. Protocols range from what is essen-
tially an efficacy trial in usual care settings to the broader enroll-
ments of “pragmatic trials.”22 In the E2E effectiveness portion, to 
minimize participant exposure to unnecessary risk, treatment 
should be limited to subgroups wherein previous probabilities 
of effectiveness and risk are most promising. Trade-offs between 
these goals will vary from case to case and will require institu-
tional review board, DSMB, and regulatory review.
Second, issues of patient access to E2E trials will require fur-
ther analysis. Could regulators approve a label with phased or 
conditional limitations on access at stages of effectiveness trials? 
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Would this take the form of clinical practice guidelines, or would 
a more complex approach be required? More generally, if the 
effectiveness trial takes place before licensing, what degree of 
discretion in controlling patient access should be accorded to 
sponsors and regulators? And how can this approach be adjusted 
to respond to the presence or absence of viable alternative treat-
ments, especially for life-threatening conditions?
Third, work is needed on whether public and private payers 
should be required, or permitted, to pay for care during an E2E 
trial. Before and after licensing, how should the costs of effective-
ness trials be supported? As data emerge on safety, efficacy, and 
effectiveness of drugs in use, how should payer reimbursement 
obligations change? In what form must such information be pre-
sented to affect payer obligations? And then how could/should 
emerging E2E evidence be used to set coverage and pricing at 
the early, middle, and late stages of the process? To what extent 
could/should market exclusivity horizons be modified if E2E 
trial results affect the timing and coverage of reimbursement?
Fourth, linked to this is the question of how emerging E2E 
evidence should be used to affect provider practices during and 
after an E2E trial and how it might be used to enhance commu-
nications with patients about what is known and what remains 
uncertain. Postauthorization measures may include clinical 
practice guidelines, changes to labels, controls of off-label use, 
control of qualified prescribers or facilities, mandatory partici-
pation in registry or observational study, and/or other forms of 
enhanced monitoring of safety and efficacy.
Fifth, in designing an E2E trial, key will be deciding which 
data collected in the efficacy portion should continue to be col-
lected in the effectiveness portion, and which data not collected 
in the efficacy portion should be added in the effectiveness por-
tion, including potentially quality of life and economic data. 
This complexity will need to be addressed in order to identify 
subgroup-specific effects and to create multivariable predictive 
models (See Supplementary Appendix online for Example of 
Such a Trial).
Finally, the heart of the E2E approach rests on generation 
and analysis of data on the effectiveness, safety, and efficacy 
of drugs that may be undergoing sponsor-administered trials 
and/or may already be in use. Who should have the power to 
compel generation and analysis of data? Who should have the 
obligation to pay? Who should own data on safety, efficacy, and 
effectiveness of drugs in use? What adjustments or changes in 
intellectual property rights may be needed to secure access to 
data needed for evaluation of effectiveness? These issues are as 
yet unresolved.
At this juncture, it is not clear whether current statutes enable 
or impede action on the specific elements of E2E trials treated in 
this article. Oye et al. address the legal foundations of adaptive 
licensing with attention to reimbursement in initial authori-
zation.23 Parallel work on the legal foundations of E2E is now 
needed.
Potential candidate treatments for testing in E2E trials
Factors relating to detection of heterogeneity of treatment 
effects could influence the choice of therapeutic area and 
agent, in addition to plans for E2E trials. Prime candidates 
include drugs for which heterogeneity in safety, efficacy, and 
effectiveness are anticipated within a diagnosis. Subgroups may 
be defined by biomarkers, genetics, clinical characteristics, the 
presence of other indications, and/or the presence of other 
drugs or supplements that may generate positive or negative 
interaction effects. Alternatively, the approach could be to use 
E2E trials of drugs that were expected to have effects in tri-
als of homogeneous samples but wherein the effects did not 
materialize. Study in more heterogeneous samples may have 
signals of effects in subgroups.
For early E2E trials, and perhaps in general, we suggest that 
study end points not be focused on mortality. In considering 
the transition from the end of the efficacy trial to the start of 
the effectiveness component, it would be ethically problem-
atic to conduct a placebo-controlled randomized trial of an 
agent that has been shown in an efficacy portion to significantly 
reduce mortality. Exceptions might be when the target popula-
tion for the effectiveness portion is so much broader than the 
efficacy trial that equipoise is still credible or when the trial 
design includes an enrollment protocol such that only those 
for whom there was true equipoise would be randomized, and 
those for whom equipoise has been dislodged would get their 
preferred treatment.12 However, at least in early E2E trials, we 
suggest using easily quantifiable outcomes other than mortality.
In addition, to learn from early E2E trials, we recommend 
that time lines for study end points be relatively short, with the 
potential of showing impact within a 1-year effectiveness trial 
component. We also suggest that early E2E trials be conducted 
in clinical domains not already heavily populated by successful 
agents. For example, doing a trial of a new proton inhibitor for 
gastroesophageal reflux disorder would fit the criteria above, 
but considering the large number of successful agents in this 
therapeutic area, the benefit in conducting such a trial would be 
minimal. Alternatively, for clinical areas with few good thera-
peutic options, such as Alzheimer’s disease or various advanced 
metastatic cancers, the benefit of assessing a promising new 
agent in an E2E trial would be substantial.
CONCLUSION
We believe that the E2E trial approach has promise for 
improving the evidentiary basis for adopting treatments in 
practice, accelerating understandings of treatment effective-
ness in subgroups with particular clinical features, and pro-
viding a framework for incorporating this information into 
the regulatory process. It also should allow investigators to 
refine the use of an agent. In addition, we see E2E trial data 
as a basis for generating multivariable predictive instruments 
that could be used as decision support for treatment of indi-
vidual patients and that reflect the heterogeneity of treatment 
effects. Finally, we see it as promoting the public good of get-
ting the right treatment to the right patient at the right time 
as early as possible.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at 
http://www.nature.com/cpt
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